KNOXVILLE, TN - VisiRose, a clinical-stage biotechnology company, has announced the introduction of a new therapy called Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT) for the treatment of severe eye infections such as infectious keratitis. Developed through a collaboration between the University of Miami Miller School of Medicine's Bascom Palmer Eye Institute (BPEI) and Provectus Biopharmaceuticals, RB PDAT combines a light-based medical device with a formulation of Provectus's Rose Bengal Sodium (RBS (LON:NWG)) to target infections caused by bacteria, fungi, and parasites.
The therapy is a response to the global challenge of antimicrobial resistance (AMR), offering a broad-spectrum solution that is potentially safe, effective, and cost-efficient. Clinical trials conducted in the United States, India, Brazil, and Mexico have demonstrated rapid resolution of infection and improved patient outcomes.
Jean-Marie Parel, Ph.D., Director at BPEI, described RB PDAT as a "revolutionary, non-invasive treatment" that utilizes light to fight infections and preserve vision. Guillermo Amescua, M.D., emphasized the role of VisiRose in making this innovation widely accessible to patients globally.
VisiRose and Provectus believe that RB PDAT represents a significant advancement in eye care, with over 500 patients showing promising results, especially in cases where traditional treatments have failed. The companies are aiming to address a gap in the $60 billion global ophthalmic market, focusing on areas affected by AMR and limited access to effective treatments.
This therapy could be a game-changer for individuals facing the risk of vision loss due to infectious keratitis. The information is based on a press release statement from VisiRose.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.